Table 1.
Demographic and clinical characteristics of the cohort.
| Variables | Total n=96 (100%) | Methylated n=47 (49%) | Unmethylated n=49 (51%) | p |
|---|---|---|---|---|
|
| ||||
| BMI (kg/m2) | Range: 18–44.6 Mean= 29.1 SD= 4.82 |
Range: 18–42.5 Mean= 30.2 SD= 4.56 |
Range: 19.1–44.6 Mean= 28.0 SD= 4.83 |
0.022 |
| Normal weight (BMI<25) | 14 (15%) | 4 (29%) | 10 (71%) | |
| Overweight (BMI 25–29.9) | 47 (49%) | 19 (40%) | 28 (60%) | |
| Obese (BMI≥30) | 35 (36%) | 24 (69%) | 11 (31%) | |
|
| ||||
| Age (yrs) | Range: 52–91 Mean= 70.8 SD= 8.72 |
Range: 52–91 Mean= 73.0 SD= 9.1 |
Range: 53–87 Mean= 68.7 SD= 7.7 |
0.017 |
| 50–59 | 12 | 4 | 8 | |
| 60–69 | 26 | 11 | 15 | |
| 70–79 | 45 | 22 | 23 | |
| ≥80 | 13 | 10 | 3 | |
|
| ||||
| Prostate volume (cc) n=90 | Mean= 82 SD= 40 Median= 78.5 Range: 22–199 |
Mean= 83 SD= 43 Median= 80 Range: 27–196 |
Mean= 81 SD= 38 Median= 78 Range: 22–199 |
0.82 |
| ≤40cc | 5 | 9 | ||
| >40cc | 40 | 36 | ||
|
| ||||
| Adjusted PSA (ng/ml) n=67 | Median= 3.40 Range: 0.21–15.90 |
Median= 4.10 Range: 0.21–15.89 |
Median= 3.21 Range: 0.52–14.40 |
0.22 |
|
| ||||
| Proscar only use | 8 (8%) | 3 | 5 | |
| Flomax only use | 34 (35%) | 17 | 17 | |
| Combined use | 35 (37%) | 18 | 17 | 1.0 |
| No medication or unable to tolerate | 19 (20%) | 9 | 10 | |
|
| ||||
| Median duration of therapy, Proscar, months (range) | 11 (1–94) | |||
|
| ||||
| Median duration of therapy, Flomax, months (range) | 17 (1–131) | |||
|
| ||||
| Comorbidities | ||||
|
| ||||
| Diabetes mellitus | 10 (10%) | 5 | 5 | 0.94 |
| Hyperlipidemia | 61 (64%) | 33 | 28 | 0.18 |
| Hypertension | 66 (69%) | 36 | 30 | 0.10 |
BMI: body mass index. SD: standard deviation. PSA: prostate specific antigen.